denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Incyte Corporation, Orca Bio, ST Shared Services LLC, a Mallinckrodt company, and Equillium Bio
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Diseases, Therapies, Adverse Events, Biological Processes
Hematology Disease Topics & Pathways:
Research, Diseases, Therapies, Adverse Events, Biological Processes
Friday, December 8, 2023: 7:00 PM-10:00 PM
Pacific Ballroom Salons 24-26
(Marriott Marquis San Diego Marina)
Chair:
Corey Cutler, Dana-Farber Cancer Institute
Disclosures:
Cutler: Sanofi: Consultancy; Pluristem Therapeutics: Other: DSMB; Allovir: Other: Data Safety Monitoring Board (DSMB); InhibRx: Consultancy; Astellas: Consultancy; Rigel: Consultancy; Oxford Immune Algorithmics: Membership on an entity's Board of Directors or advisory committees; Cimeio: Membership on an entity's Board of Directors or advisory committees.
Speakers:
Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center
,
Carrie L. Kitko, MD, Vanderbilt University
and
Hannah Choe, MD, The Ohio State University Wexner Medical Center
Disclosures:
Perales: Sellas Life Sciences: Consultancy; Syncopation: Honoraria; Omeros: Consultancy, Current equity holder in publicly-traded company, Honoraria; Cidara Therapeutics: Consultancy, Other; Karyopharm: Consultancy, Honoraria; Vor Biopharma: Consultancy, Honoraria; VectivBio AG: Consultancy, Honoraria; Celgene: Honoraria; Exevir: Consultancy, Honoraria; Merck: Consultancy, Honoraria; Medigene: Consultancy, Other; Novartis: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria; Orcabio: Consultancy, Current equity holder in publicly-traded company, Honoraria; Nektar Therapeutics: Consultancy, Honoraria, Research Funding; Miltenyi Biotec: Consultancy, Honoraria, Research Funding; Equillium: Consultancy, Honoraria; MorphoSys: Consultancy, Honoraria; Caribou: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Allovir: Consultancy; Adicet: Honoraria; Astellas: Consultancy, Honoraria; NexImmune: Consultancy, Current equity holder in publicly-traded company; Incyte: Consultancy, Honoraria, Research Funding; Kite: Consultancy, Honoraria, Research Funding; Servier: Other; Miltenyi Biotec: Honoraria; DSMB: Other; Allogene: Research Funding. Kitko: Horizon: Membership on an entity's Board of Directors or advisory committees. Choe: NIH National Cancer Institute: Research Funding; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Receipt of equipment, materials, drugs to institution; Opna: Other: Receipt of equipment, materials, drugs to institution, Research Funding; MJH Life Sciences: Honoraria; Actinium Pharmaceuticals: Other: Support for attending meetings and/or travel.
The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together 4 clinical experts to highlight novel agents in the management of acute and chronic GvHD, as well as prophylaxis care. Novel and investigational approaches will be considered across key decision points in care, with ample discussion from the expert panel and from “the floor” on how we treat GvHD today... and tomorrow!
See more of: Friday Satellite Symposia